Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies.
cancer biology
glioblastoma
immunotherapy
microenvironment
regulatory T cell
tumor-associated dendritic cell
tumor-associated macrophage
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
04 02 2020
04 02 2020
Historique:
received:
25
09
2019
accepted:
30
01
2020
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
10
4
2021
Statut:
epublish
Résumé
Cancer immunotherapy by immune checkpoint blockade has proven its great potential by saving the lives of a proportion of late stage patients with immunogenic tumor types. However, even in these sensitive tumor types, the majority of patients do not sufficiently respond to the therapy. Furthermore, other tumor types, including glioblastoma, remain largely refractory. The glioblastoma immune microenvironment is recognized as highly immunosuppressive, posing a major hurdle for inducing immune-mediated destruction of cancer cells. Scattered information is available about the presence and activity of immunosuppressive or immunostimulatory cell types in glioblastoma tumors, including tumor-associated macrophages, tumor-infiltrating dendritic cells and regulatory T cells. These cell types are heterogeneous at the level of ontogeny, spatial distribution and functionality within the tumor immune compartment, providing insight in the complex cellular and molecular interplay that determines the immune refractory state in glioblastoma. This knowledge may also yield next generation molecular targets for therapeutic intervention.
Identifiants
pubmed: 32014107
doi: 10.7554/eLife.52176
pii: 52176
pmc: PMC7000215
doi:
pii:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2020, Pombo Antunes et al.
Déclaration de conflit d'intérêts
AP, IS, JD, BN, KM, JV No competing interests declared
Références
Neuro Oncol. 2011 Mar;13(3):324-33
pubmed: 21149254
Science. 2014 May 23;344(6186):921-5
pubmed: 24812208
Cancer Immunol Immunother. 2016 Dec;65(12):1555-1567
pubmed: 27734112
Cancer Discov. 2016 Dec;6(12):1382-1399
pubmed: 27663893
Brain. 2006 Sep;129(Pt 9):2426-35
pubmed: 16835250
J Neurooncol. 2007 Jun;83(2):145-52
pubmed: 17216339
Front Oncol. 2019 Feb 26;9:69
pubmed: 30863720
Nat Commun. 2016 Dec 23;7:13720
pubmed: 28008905
J Immunother Cancer. 2016 May 17;4:28
pubmed: 27190629
Nat Med. 2018 Aug;24(8):1094-1096
pubmed: 30082860
Neuro Oncol. 2014 Jan;16(1):21-8
pubmed: 24335554
Clin Cancer Res. 2018 Sep 1;24(17):4175-4186
pubmed: 29437767
Neuro Oncol. 2011 Dec;13(12):1308-23
pubmed: 21908444
Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):14254-14259
pubmed: 31235603
Nat Med. 2018 Aug;24(8):1178-1191
pubmed: 29942093
Science. 2016 May 20;352(6288):aad3018
pubmed: 27199435
Immunity. 2018 Mar 20;48(3):599
pubmed: 29562204
Nature. 2019 Jan;565(7738):234-239
pubmed: 30568305
Sci Immunol. 2017 May 19;2(11):null
pubmed: 28763794
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
J Clin Invest. 2017 Apr 3;127(4):1425-1437
pubmed: 28319047
J Neurooncol. 2014 Jan;116(2):251-9
pubmed: 24276989
Blood. 2008 Apr 15;111(8):4233-44
pubmed: 18272812
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6086-6091
pubmed: 28533380
Nature. 2013 Sep 12;501(7466):252-6
pubmed: 23913274
Oncoimmunology. 2017 Aug 8;6(11):e1358839
pubmed: 29147621
Cancer Immunol Immunother. 2008 Dec;57(12):1807-16
pubmed: 18392618
Proc Natl Acad Sci U S A. 2020 Jan 14;117(2):1129-1138
pubmed: 31879345
Cancer Cell. 2016 Aug 8;30(2):324-336
pubmed: 27424807
Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23714-23723
pubmed: 31712430
Cell Metab. 2019 Jul 2;30(1):201-211.e6
pubmed: 31056286
Cancers (Basel). 2019 Apr 15;11(4):null
pubmed: 30991681
Oncotarget. 2019 May 3;10(33):3129-3143
pubmed: 31139325
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
Clin Cancer Res. 2019 Mar 15;25(6):1913-1922
pubmed: 30498094
Nat Med. 2019 Mar;25(3):470-476
pubmed: 30742120
Nat Commun. 2019 Jan 25;10(1):448
pubmed: 30683885
Nat Rev Clin Oncol. 2019 Aug;16(8):509-520
pubmed: 30733593
J Control Release. 2019 Aug 28;308:109-118
pubmed: 31255690
Nat Commun. 2018 Oct 17;9(1):4313
pubmed: 30333482
Cancer Res. 2018 Oct 1;78(19):5574-5585
pubmed: 29921698
Clin Cancer Res. 2018 Aug 15;24(16):3792-3802
pubmed: 29593027
Nat Med. 2019 Mar;25(3):477-486
pubmed: 30742122
Cancer Res. 2010 Jul 15;70(14):5728-39
pubmed: 20570887
J Neurooncol. 2015 Apr;122(2):293-301
pubmed: 25579983
Cell Rep. 2017 Oct 31;21(5):1399-1410
pubmed: 29091775
PLoS One. 2013;8(3):e59082
pubmed: 23527092
Neuro Oncol. 2018 Nov 12;20(12):1566-1572
pubmed: 29733389
Immunity. 2016 Nov 15;45(5):1122-1134
pubmed: 27851913
Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10672-E10681
pubmed: 30348759
Neuro Oncol. 2015 Jun;17(6):801-9
pubmed: 25618892
Cancer Cell. 2013 Dec 9;24(6):695-709
pubmed: 24332039
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14
pubmed: 23412337
Nat Med. 2013 Oct;19(10):1264-72
pubmed: 24056773
Br J Cancer. 2014 Mar 4;110(5):1179-88
pubmed: 24423923
Sci Immunol. 2019 Jan 25;4(31):
pubmed: 30679199
J Immunother Cancer. 2019 May 29;7(1):142
pubmed: 31142380
Science. 2014 Jun 20;344(6190):1396-401
pubmed: 24925914
J Clin Invest. 2019 Jan 2;129(1):137-149
pubmed: 30307407
Cell. 2014 Apr 24;157(3):580-94
pubmed: 24726434
Science. 2019 Jan 25;363(6425):
pubmed: 30679343
J Exp Med. 2018 Oct 1;215(10):2536-2553
pubmed: 30201786
Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):997-1006
pubmed: 30602457
Cancer Cell. 2014 Nov 10;26(5):638-52
pubmed: 25446897
Cancer Res. 2016 Oct 1;76(19):5671-5682
pubmed: 27530322
Immunity. 2016 Nov 15;45(5):1135-1147
pubmed: 27851914
Clin Cancer Res. 2019 Jun 15;25(12):3643-3657
pubmed: 30824583
ACS Nano. 2019 Apr 23;13(4):4028-4040
pubmed: 30916923
Cell. 2019 Apr 18;177(3):556-571.e16
pubmed: 30955881
Br J Cancer. 2015 Dec 1;113(11):1642
pubmed: 26625224
Cell. 2016 Jan 28;164(3):550-63
pubmed: 26824661
Nature. 2019 Jan;565(7738):240-245
pubmed: 30568303
J Neuroimmunol. 2010 Aug 25;225(1-2):195-9
pubmed: 20537408
Clin Cancer Res. 2019 Oct 1;25(19):5743-5751
pubmed: 31040150
Clin Cancer Res. 2012 Nov 15;18(22):6110-21
pubmed: 22932670
Cell. 2019 Aug 8;178(4):835-849.e21
pubmed: 31327527
Clin Cancer Res. 2019 Dec 1;25(23):6948-6957
pubmed: 31537527
Front Oncol. 2019 Feb 22;8:656
pubmed: 30854331
Lancet Oncol. 2019 Jul;20(7):948-960
pubmed: 31160251
Nat Med. 2018 Nov;24(11):1649-1654
pubmed: 30297909
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Antioxid Redox Signal. 2016 Nov 10;25(14):775-791
pubmed: 27020982
J Neurooncol. 2019 Jun;143(2):241-249
pubmed: 31025274
JCI Insight. 2018 Nov 2;3(21):
pubmed: 30385717
Clin Cancer Res. 2013 Sep 15;19(18):4951-60
pubmed: 23864165
Cancer Treat Rev. 2018 Sep;69:121-131
pubmed: 29966936
Clin Cancer Res. 2017 Apr 15;23(8):1898-1909
pubmed: 28411277
J Clin Invest. 2010 Mar;120(3):694-705
pubmed: 20179352
Br J Cancer. 2011 Jun 7;104(12):1805-9
pubmed: 21587260
J Clin Oncol. 2018 May 10;36(14):1419-1427
pubmed: 29432077
Nat Neurosci. 2019 May;22(5):729-740
pubmed: 30962630
Oncoimmunology. 2018 Oct 16;8(1):e1525243
pubmed: 30546966
Cancer Immunol Res. 2019 Dec;7(12):1928-1943
pubmed: 31530559
Cell. 2017 Jun 15;169(7):1342-1356.e16
pubmed: 28622514
Oncol Res. 2018 Mar 5;26(2):173-182
pubmed: 28109087
Nat Neurosci. 2019 Jun;22(6):1021-1035
pubmed: 31061494
Oncotarget. 2018 Apr 17;9(29):20681-20697
pubmed: 29755681
Cell Rep. 2016 Nov 22;17(9):2445-2459
pubmed: 27840052
Nat Commun. 2019 Aug 28;10(1):3850
pubmed: 31462642
Cell. 2017 Jun 1;169(6):1130-1141.e11
pubmed: 28552348
Oncoimmunology. 2018 Apr 25;7(7):e1448329
pubmed: 29900065
Genome Biol. 2017 Dec 20;18(1):234
pubmed: 29262845
N Engl J Med. 2018 Jul 12;379(2):150-161
pubmed: 29943666
Cancer Cell. 2019 Jun 10;35(6):868-884.e6
pubmed: 31185211
Cancer Res. 2017 May 1;77(9):2266-2278
pubmed: 28235764
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
Nat Med. 2018 Sep;24(9):1459-1468
pubmed: 30104766
Cell Rep. 2019 Apr 2;27(1):226-237.e4
pubmed: 30943404
Nat Med. 2018 Nov;24(11):1655-1661
pubmed: 30297911
Nat Med. 2019 Mar;25(3):462-469
pubmed: 30742119
Front Immunol. 2019 Jul 31;10:1799
pubmed: 31417566
Neuro Oncol. 2017 Oct 19;19(11):1460-1468
pubmed: 28531337
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633
Genes Dev. 2015 Jun 15;29(12):1203-17
pubmed: 26109046
Front Oncol. 2018 Oct 23;8:464
pubmed: 30406030